VERRICA PHARMACEUTICALS INC.

(VRCA)
  Report
Delayed Nasdaq  -  04:00 2022-08-16 pm EDT
3.780 USD   -3.32%
08/11VERRICA PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/11Verrica Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
08/11VERRICA PHARMACEUTICALS : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Verrica Pharmaceuticals : Company Presentation

06/29/2022 | 05:52pm EDT

Company Overview

June 29, 2022

Copyright © 2022 Verrica

Pharmaceuticals. All rights reserved.

1

Disclaimer

Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica's own internal estimates and research. While Verrica believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Verrica believes its internal research is reliable, such research has not been verified by any independent source.

This presentation contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding future results of operations and financial position, business strategy, interactions with the FDA with regard to the resolution of the CRL, the timing of an NDA resubmission, potential approval of the NDA for VP-102, the potential benefits and potential commercialization of VP-102 for the treatment of molluscum, if approved, current and prospective product candidates, planned clinical trials and preclinical activities, product approvals, degree of market acceptance of approved products, research and development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated product candidates, and the potential payments and benefits to Verrica of the license agreement with Torii, are forward-looking statements. The words "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these

identifying words.

The information in this presentation, including without limitation the forward- looking statements contained herein, represent our views as of the date of this presentation. Although we believe the expectations reflected in such forward- looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The forward-looking statements in this presentation involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, our reliance on third parties over which we may not always have full control, and other risks and uncertainties that are described in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (SEC) on March 2, 2022, and our other filings made with the SEC. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. There can be no assurance that the opportunity will meet your investment objectives, that you will receive a return of all or part of such investment. Investment results may vary significantly over any given time period. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. We recommend that investors independently evaluate specific investments and strategies.

2

Copyright © 2022 Verrica Pharmaceuticals. All rights reserved.

Investment Highlights

Focused on Clinician-Administered Therapies With Potential for Reimbursement as a Medical Benefit

YCANTH™ (VP-102)

  • In Development to Address Two of the Largest Unmet Needs in Dermatology
    • U.S. prevalence of ~6 million in molluscum contagiosum(1) and ~22 million in common warts(2)
    • No FDA-approved drugs to treat molluscum or warts
  • Innovative Product Candidate
    • Proprietary drug-device combination of formulation and single-use applicator
  • Physician Acceptance
    • 95% of Pediatric Dermatologists have used API(3)
  • Payer Research Suggests Favorable Reimbursement Landscape
  • Exclusive License for Torii Pharmaceutical to Develop and Commercialize VP-102 in Japan
  • NDA resubmission expected Q1 2023

Dermatological Oncology

  • Worldwide rights for dermatological oncology, including basal cell and squamous cell carcinomas and non-metastatic melanoma, to LTX-315
    • First-in-classoncolytic peptide injected directly into tumor
  • Positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncology trials
  • Verrica to focus initially on development to treat basal cell and squamous cell carcinomas
  • 5.4 million diagnoses annually in the U.S. of basal and squamous cell skin cancers(4); patients typically treated with surgery
  • FDA acceptance of IND in November 2021; first patient dosed in Phase 2 study for treatment of Basal Cell Carcinoma in April 2022

  • Proven Team and Strong Balance Sheet
  • Industry-leading,experienced management team with extensive dermatology product launch experience
  • $21.9M cash, cash equivalents and marketable securities as of March 31, 2022 (excludes restricted cash)
  1. Prevalence in the US of 5.1% to 11.5% in children aged 0-16 years. (Fam Pract. 2014 Apr;31(2):130-6). US Census estimates ~69.4MM children aged 0 to 16 years in 2016.
  2. IMS National Disease and Therapeutic Index (NDTI) Rolling 5 Years Ending June 2016. Nguyen et al, Laser Treatment of Nongenital Verrucae A Systemic Review. JAMA Dermatology. 2016; 152(9): 1025-1033
  3. Based on a survey of 115 dermatologists the results of which have been extrapolated to pediatric dermatologists.
  4. Rogers JAMA Derm 2015; https://www.aad.org/media/stats-skin-cancer; https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/
  5. Timing of clinical trials subject to change.3

Copyright © 2022 Verrica Pharmaceuticals. All rights reserved.

Verrica: Striving to Change the Game in Medical Dermatology

  • Potential first and only FDA-approved product to treat Molluscum Contagiosum
  • Innovative distribution model to eliminate physician cost of acquiring YCANTH
    • Forward-deployedbased inventory model to allow physicians to pay for inventory only after the claim has been adjudicated and the patient agrees to treatment through RFID technology
  • Enhanced physician revenue opportunity
    • Continued reimbursement under the CPT codes 11710 and 17111
    • Margin on sale of the product (typically 6%-10% of ASP dependent on health plan)
  • HCP-administeredprocedure in office typically falls under the medical benefit with an assigned permanent J-Code
  • Patient responsibility typically averages 20% co-insurance off list price, before manufacturer co-pay applied

4

Copyright © 2022 Verrica Pharmaceuticals. All rights reserved.

Our Product Portfolio

LTX-315VP-103VP-102 YCANTH

PRE-IND

PHASE 2

PHASE 3

NDA

NEXT EXPECTED MILESTONE

Molluscum Contagiosum

NDA resubmission

expected Q1 2023

External Genital Warts

Initiate Phase 3 in 1H 2024 [b]

Common Warts

[a]

Evaluate potential second

Phase 2 trial[c]

Plantar Warts

Initiate Phase 2 trial[d]

Dermatological

Phase 2 first patient

Oncology [e]

dosed: April 2022

[a]

Originally designed Phase 2 program completed.

[b]

Timing of clinical trials for External Genital Warts may be subject to change.

[c]

Company evaluating potential for conducting an additional Phase 2 trial based on FDA feedback for Phase 3 trial protocol.

[d]

Timing for initiating clinical trials for Plantar Warts to be determined.

[e]

License excludes metastatic melanoma and metastatic merkel cell carcinoma. Phase 2 study initiated in April 2022 for the treatment of

Basal Cell Carcinoma.

5

Copyright © 2022 Verrica Pharmaceuticals. All rights reserved.

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Verrica Pharmaceuticals Inc. published this content on 29 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 June 2022 21:51:09 UTC.


© Publicnow 2022
All news about VERRICA PHARMACEUTICALS INC.
08/11VERRICA PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Conditi..
AQ
08/11Verrica Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Mo..
CI
08/11VERRICA PHARMACEUTICALS : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/11Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q2 Loss $-0.32
MT
08/11Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
GL
08/11Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
GL
08/01Verrica Pharmaceuticals Receives $8 Million Milestone Payment From Torii Pharmaceutical..
MT
08/01Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of..
GL
08/01Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of..
AQ
07/20BERGER MONTAGUE INVESTIGATES SECURIT : VRCA) - VERRICA PHARMACEUTICALS, INC. - Lead Plaint..
PR
More news
Analyst Recommendations on VERRICA PHARMACEUTICALS INC.
More recommendations
Financials (USD)
Sales 2022 5,19 M - -
Net income 2022 -33,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,79x
Yield 2022 -
Capitalization 155 M 155 M -
Capi. / Sales 2022 30,0x
Capi. / Sales 2023 16,3x
Nbr of Employees 38
Free-Float 46,9%
Chart VERRICA PHARMACEUTICALS INC.
Duration : Period :
Verrica Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERRICA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 3,78 $
Average target price 10,00 $
Spread / Average Target 165%
EPS Revisions
Managers and Directors
Ted White President, Chief Executive Officer & Director
Terry Kohler Chief Financial & Accounting Officer
Paul B. Manning Chairman
Gary Goldenberg Chief Medical Officer
Eugene Scavola Executive Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
VERRICA PHARMACEUTICALS INC.-57.31%161
JOHNSON & JOHNSON-2.91%436 680
ELI LILLY AND COMPANY13.66%298 298
PFIZER, INC.-15.75%279 215
ROCHE HOLDING AG-16.14%277 502
ABBVIE INC.5.09%251 582